223 related articles for article (PubMed ID: 32355275)
1. Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40.
Wenthe J; Naseri S; Hellström AC; Wiklund HJ; Eriksson E; Loskog A
Cancer Gene Ther; 2020 Dec; 27(12):948-959. PubMed ID: 32355275
[TBL] [Abstract][Full Text] [Related]
2. Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy.
Wenthe J; Naseri S; Labani-Motlagh A; Enblad G; Wikström KI; Eriksson E; Loskog A; Lövgren T
Cancer Immunol Immunother; 2021 Oct; 70(10):2851-2865. PubMed ID: 33666760
[TBL] [Abstract][Full Text] [Related]
3. Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus.
Eriksson E; Milenova I; Wenthe J; Ståhle M; Leja-Jarblad J; Ullenhag G; Dimberg A; Moreno R; Alemany R; Loskog A
Clin Cancer Res; 2017 Oct; 23(19):5846-5857. PubMed ID: 28536305
[No Abstract] [Full Text] [Related]
4. Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models.
Wenthe J; Eriksson E; Hellström AC; Moreno R; Ullenhag G; Alemany R; Lövgren T; Loskog A
J Transl Med; 2023 Jul; 21(1):506. PubMed ID: 37501121
[TBL] [Abstract][Full Text] [Related]
5. Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene.
Fernandes MS; Gomes EM; Butcher LD; Hernandez-Alcoceba R; Chang D; Kansopon J; Newman J; Stone MJ; Tong AW
Clin Cancer Res; 2009 Aug; 15(15):4847-56. PubMed ID: 19622582
[TBL] [Abstract][Full Text] [Related]
6. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG
Hum Gene Ther; 2010 Apr; 21(4):439-50. PubMed ID: 19922169
[TBL] [Abstract][Full Text] [Related]
7. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A
Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493
[TBL] [Abstract][Full Text] [Related]
8. Modulating Oncolytic Adenovirus Immunotherapy by Driving Two Axes of the Immune System by Expressing 4-1BBL and CD40L.
Lu SC; Hansen MJ; Hemsath JR; Parrett BJ; Zell BN; Barry MA
Hum Gene Ther; 2022 Mar; 33(5-6):250-261. PubMed ID: 34731019
[TBL] [Abstract][Full Text] [Related]
9. Novel Combination Oncolytic Adenoviral Gene Therapy Armed with Dm-dNK and CD40L for Breast Cancer.
Wang Q; Yang M; Zhang Y; Zhong L; Zheng X
Curr Gene Ther; 2019; 19(1):54-65. PubMed ID: 30848201
[TBL] [Abstract][Full Text] [Related]
10. CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling.
Naseri S; Cordova MM; Wenthe J; Lövgren T; Eriksson E; Loskog A; Ullenhag GJ
J Cell Mol Med; 2024 Apr; 28(7):e18162. PubMed ID: 38494863
[TBL] [Abstract][Full Text] [Related]
11. CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging.
Parviainen S; Ahonen M; Diaconu I; Hirvinen M; Karttunen Å; Vähä-Koskela M; Hemminki A; Cerullo V
Gene Ther; 2014 Feb; 21(2):195-204. PubMed ID: 24305418
[TBL] [Abstract][Full Text] [Related]
12. Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes.
Labani-Motlagh A; Naseri S; Wenthe J; Eriksson E; Loskog A
Mol Ther Oncolytics; 2021 Mar; 20():508-518. PubMed ID: 33738337
[TBL] [Abstract][Full Text] [Related]
13. Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans.
Cerullo V; Koski A; Vähä-Koskela M; Hemminki A
Adv Cancer Res; 2012; 115():265-318. PubMed ID: 23021247
[TBL] [Abstract][Full Text] [Related]
14. Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy.
Marchica V; Franceschi V; Vescovini R; Storti P; Vicario E; Toscani D; Zorzoli A; Airoldi I; Dalla Palma B; Campanini N; Martella E; Mancini C; Costa F; Donofrio G; Giuliani N
J Hematol Oncol; 2020 Jul; 13(1):89. PubMed ID: 32653014
[TBL] [Abstract][Full Text] [Related]
15. Infection and killing of multiple myeloma by adenoviruses.
Senac JS; Doronin K; Russell SJ; Jelinek DF; Greipp PR; Barry MA
Hum Gene Ther; 2010 Feb; 21(2):179-90. PubMed ID: 19788385
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic virotherapy - Forging its place in the immunomodulatory paradigm for Multiple Myeloma.
Cook J; Acosta-Medina AA; Peng KW; Lacy M; Russell S
Cancer Treat Res Commun; 2021; 29():100473. PubMed ID: 34673439
[TBL] [Abstract][Full Text] [Related]
17. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model.
El-Shemi AG; Ashshi AM; Na Y; Li Y; Basalamah M; Al-Allaf FA; Oh E; Jung BK; Yun CO
J Exp Clin Cancer Res; 2016 May; 35():74. PubMed ID: 27154307
[TBL] [Abstract][Full Text] [Related]
18. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.
Naik S; Nace R; Barber GN; Russell SJ
Cancer Gene Ther; 2012 Jul; 19(7):443-50. PubMed ID: 22522623
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts.
Radhakrishnan S; Miranda E; Ekblad M; Holford A; Pizarro MT; Lemoine NR; Halldén G
Hum Gene Ther; 2010 Oct; 21(10):1311-25. PubMed ID: 20497039
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic Virotherapy and Microenvironment in Multiple Myeloma.
Marchica V; Costa F; Donofrio G; Giuliani N
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
